ONC.AI is a healthcare technology company specializing in the development of AI-driven solutions for oncology and cancer care.

Oncology, AI, genomics, proteomics, radiomics, ML, diagnostics

Digitalis Ventures

Accomplice

KdT Ventures

BlueCross BlueShield Venture Partners

T. Chen Fong

Frederic Kerrest

Jonathan J. Fleming

Stanley M. Marks

The Blue Venture Fund

Action Potential Venture Capital

Life Extension Ventures

MassMutual

Onc.AI

We're absolutely thrilled to announce Kevin Masukawa Ph.D. has been appointed Chief Commercial Officer at Onc.AI -- where he'll lead Sales, Marketing and Market-Access organizations. Kevin brings significant oncology sales and strategic marketing experience with past tenures at L.E.K, Genentech (12+ years) and most recently as VP Oncology Marketing at Natera where he architected and executed the market adoption strategy for the breakthrough Signatera test for Molecular Residual Disease (MRD) in solid tumors.  Kevin holds a PhD in Chemical Biology from UCSF and BSc in Biochemistry from UCSD.

If you are at ASCO today, join us now for our last poster session presented by Dr. George Simon, and following discussion at 4:30pm to learn more about care delivery and regulatory policy.

📚 Abstract Title: "AI-based radiomic biomarkers to predict PD-(L)1 immune checkpoint inhibitor response within PD-L1 high/low/negative expression categories in stage IV NSCLC."
🗓️ Poster Session Display Date and Time:
6/5/2023, 1:15 PM-4:15 PM
📍 Poster Board Number: 111

🗣️ Poster Discussion Session Date and Time:
6/5/2023, 4:30 PM-6:00 PM
🎙️ Session Type/Title: Poster Discussion Session - Care Delivery and Regulatory Policy

Don't miss this exciting opportunity to explore the innovative research on AI-based radiomic biomarkers and their potential to predict PD-(L)1 immune checkpoint inhibitor response in stage IV NSCLC patients across different PD-L1 expression categories!

#ASCO2023 #NSCLC #AIinMedicine #Immunotherapy 

Good morning ☀  If you are in Chicago at #ASCO2023, we invite you to attend an exciting poster session this morning: join us to explore the remarkable findings presented by Dr. Chiharu Sako in the field of non-small cell metastatic lung cancer.

Poster Details:
🔍 Temporary Abstract Submission ID: 418076
📑 Abstract Number for Publication: 9124
📚 Abstract Title: "Multi-center real-world data curation and assessment of tumor growth rate and overall survival in advanced NSCLC treated with PD-(L)1 immune checkpoint inhibitor therapy."
🗓️ Session Date and Time:
6/4/2023, 8:00 AM-11:00 AM

Don't miss this opportunity to delve into the latest advancements in the management of advanced NSCLC and engage in meaningful discussions, exchange knowledge, and connect with fellow professionals in the field.

#ASCO2023 #LungCancerResearch #NSCLC  #MedicalAdvancements

Join us at #ASCO2023 to learn about our AI-powered clinical management products. Don't miss our abstract presentations: 

📌 Abstract #9124, Poster #112 (Chiharu Sako, PhD -- Onc.AI) 
📌 Abstract #1517, Poster #111 (George R. Simon, MD, FACP, FCCP -- Moffitt Cancer Center)

Additionally, we're hosting an exclusive gathering on Sunday at 6:30pm for our friends, clinical advisors and partners with limited spots available. 

Calling medical oncologists interested in AI and immunotherapy-focused clinical management solutions. Reach out to contact@onc.ai with "High Spirits" in the subject line and we'll follow-up to get you in! 

Experience the future of oncology with us at #ASCO2023!

#OncologyInnovation #AIinMedicine #ClinicalManagement #Immunotherapy

AI:ONC

ONC.AI

Analysis Not Available